June 30, 2020

Antibe Therapeutics Announces Closing of $28.75 Million Bought Deal Offering

NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES TORONTO, CANADA — (June 30, 2020) — Antibe Therapeutics Inc. (TSXV: ATE) announced that it closed its previously announced bought deal public offering of 62,500,000 units of the Company (the “Units“) at a price of $0.40 per Unit (the “Offering Price“) plus … Continued

read
June 9, 2020

Antibe Therapeutics Announces $25 Million Bought Deal Unit Offering

NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES TORONTO, CANADA — (June 9, 2020) — Antibe Therapeutics Inc. (TSXV: ATE) today announced that it has entered into a bought deal agreement with a syndicate of underwriters led by Bloom Burton Securities Inc. and including Echelon Wealth Partners Inc., Paradigm Capital … Continued

read
June 1, 2020

Antibe Therapeutics Announces Positive Top-Line Data from Phase 2B Dose-Ranging, Efficacy Study for ATB-346

– ATB-346 demonstrates superiority to placebo in reducing osteoarthritis pain – – ATB-346 is more potent than expected; lowest effective dose still to be established – – Antibe plans pivotal Phase 2/3 adaptive registration trial – TORONTO, CANADA — (June 1, 2020) — Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that … Continued

read
May 6, 2020

Antibe Therapeutics Announces the Hiring of Chief Medical Officer

– Dr. Joseph Stauffer, an anesthesiologist with deep clinical and regulatory experience, fills a key position as Antibe prepares for late-stage development and partnering – TORONTO, CANADA — (May 6, 2020) — Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the hiring of Dr. Joseph Stauffer in the new role of Chief … Continued

read
February 28, 2020

Antibe Therapeutics Announces Enrollment of Last Patient in Phase 2B Dose-Ranging, Efficacy Study of Lead Drug, ATB-346

TORONTO, CANADA — (February 28, 2020) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce that the last patient has been enrolled and is on treatment in the Phase 2B dose-ranging, efficacy study of Antibe’s lead drug, … Continued

read
February 25, 2020

Antibe Therapeutics Provides Corporate Update and Reports Q3 2020 Interim Financial and Operating Results

TORONTO, CANADA — (February 25, 2020) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to provide a corporate update in conjunction with the filing of its financial and operating results for the fiscal quarter ended December 31, 2019. … Continued

read
February 24, 2020

Antibe Therapeutics Announces Research Publication Demonstrating Markedly Enhanced Pain Relief and Increased Safety of Second Pipeline Drug

TORONTO, CANADA — (February 24, 2020) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce the publication of a multi-national study entitled “Enhanced Analgesic Effects and GI Safety of A Novel Hydrogen Sulfide-Releasing Anti- Inflammatory Drug (ATB-352): … Continued

read

archives

Attention

This is an external link. Click “OK” to continue.

CANCEL OK